$154.94
-2.40 (-1.53%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PTGX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional · 2 with posted results
Held by 13 tracked-famous managers (Duquesne Family Office LLC, MARSHALL WACE, LLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Schonfeld Strategic Advisors LLC, POLEN CAPITAL MANAGEMENT LLC, +8 more) · FINRA short interest 14.2 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraNCT06033586HematocritOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Open-label rusfertide | Polycythemia Vera | 46 | 2026-04-01 | 2025-08-06 |
| A Phase 3 Study of Rusfertide in Patients With Polycythemia VeraNCT05210790Proportion of subjects achieving a response who receive rusfertide compared to placebo.Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Placebo, Rusfertide | Polycythemia Vera | 293 | 2025-02-21actual | 2025-08-07 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.NCT07153146Incidence and severity of treatment-emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: PN-881 Oral Solution, PN-881 Oral Tablet, Placebo | Healthy Volunteer | 146 | 2026-07-29actual | 2026-08-05 |
| PTG-300 in Patients With Polycythemia Vera and Elevated HematocritNCT04767802Evaluate PTG-300's efficacy in subjects with PV and baseline elevated hematocrit.Open-label · Treatment | Phase 2 | Completed | Drug: PTG-300 | Polycythemia Vera | 20 | 2023-03-15actual | 2024-03-18 |
| PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)NCT04504383Proportion of subjects achieving clinical remission at Week 12 compared to placebo.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: PN-943, Placebo | Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe | 169 | 2023-02-16actual | 2023-04-25 |
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)NCT04057040Proportion of responders during the blinded randomized withdrawal period (Week 29 to Week 41).Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: PTG-300, Placebo | Polycythemia Vera | 70 | 2023-02-14actual | 2025-08-07 |
| Pharmacokinetics of PN-232 in Healthy VolunteersNCT04819620Safety of PN-232Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PN-232, Placebo | Healthy Subjects | 48 | 2021-12-17actual | 2022-10-03 |
| PTG-300 in Subjects With Hereditary HemochromatosisNCT04202965results2023-06-15Effect of PTG-300 on Transferrin SaturationOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PTG-300 | Hereditary Hemochromatosis | 16 | 2021-10-06actual | 2025-08-20 |
| Pharmacokinetics of PN-235 in Healthy VolunteersNCT04621630Safety of PN-235Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PN-235, Placebo | Healthy Volunteers | 107 | 2021-09-19actual | 2022-02-18 |
| Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy VolunteersNCT04516382Bioavailability of PTG-300Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: PTG-300 | Healthy Volunteers | 12 | 2021-01-12actual | 2021-09-16 |
| Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic AnemiaNCT03802201NTD: Proportion of responders at each doseOpen-label · Treatment | Phase 2 | Completed | Drug: PTG-300 | β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia | 63 | 2020-07-31actual | 2021-07-16 |
| Safety Study for Beta Thalassemia Subjects on PTG-300NCT04054921Proportion of subjects with side effects and severity of side effects will be tabulatedOpen-label · Treatment | Phase 2 | Completed | Drug: PTG-300 | β-thalassemia, Ineffective Erythropoiesis | 34 | 2020-07-31actual | 2021-07-16 |
| Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisNCT02895100results2021-03-22Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With PlaceboRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Data Monitoring Committee discontinued the trial due to futility-based outcome | Drug: PTG-100, Placebo | Ulcerative Colitis | 98 | 2018-03-26actual | 2025-08-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19